New targets for the development of a drug treatment for obesity and type 2 diabetes

Digital providers come to the fore to support global mental health during pandemic
10 February 2021
‘Gamechanger’ drug for treating obesity cuts body weight by 20%
10 February 2021

New targets for the development of a drug treatment for obesity and type 2 diabetes

The GIP receptor in the central nervous system plays a crucial role in the regulation of body weight and food intake. This is shown by a recent study by Helmholtz Zentrum München, ETH Zurich and the German Center for Diabetes Research (DZD). The study, which has now been published in Cell Metabolism, identifies new targets for the development of a drug treatment for obesity and type 2 diabetes.

Comments are closed.